nach oben

Erschienen in:

01.06.2019 | Case report

Nivolumab/pembrolizumab

Various toxicities: 9 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective study of 17 HIV-positive cancer patients treated at Grady Memorial Hospital and Duke University Hospital, USA, nine male patients aged 43−62 years were described, who developed pneumonitis (1 patient), colitis and rash (1 patient), fatigue and hypothyroidism (1 patient), elevated TSH (3 patients), hypothyroidism (1 patient), hyperglycaemia and hypothyroidism (1 patient) and fatigue (1 patient) following treatment with nivolumab or pembrolizumab. …

Bari S, et al. Outcomes of programmed cell death protein 1 (PD-1) and programmed death-ligand 1(PD-L1) inhibitor therapy in HIV patients with advanced cancer. Journal of Oncology 2019: 2989048, 1 Jan 2019. Available from: URL: http://doi.org/10.1155/2019/2989048 - USA

Titel: Nivolumab/pembrolizumab
Various toxicities: 9 case reports
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63804-4

Springer Medizin

Nivolumab/pembrolizumab

Various toxicities: 9 case reports

Excerpt

Weitere Artikel der Ausgabe 1/2019

Antineoplastics

Antibacterials

Amisulpride overdose

Pramipexole overdose

Propylthiouracil

Mycophenolate mofetil/prednisolone/tacrolimus

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Antineoplastics

Antibacterials

Amisulpride overdose

Pramipexole overdose

Propylthiouracil

Mycophenolate mofetil/prednisolone/tacrolimus